Tommasin, Silvia http://orcid.org/0000-0001-9088-7968
De Giglio, Laura
Ruggieri, Serena
Petsas, Nikolaos
Giannì, Costanza
Pozzilli, Carlo
Pantano, Patrizia
Funding for this research was provided by:
Italian Federation of multiple sclerosis
Article History
Received: 10 July 2018
Revised: 21 September 2018
Accepted: 25 September 2018
First Online: 1 October 2018
Compliance with ethical standards
:
: During the conduct of the study ST reports grants from FISM; LDG received speaking onoraria from Genzyme and Novartis, travel grant from Biogen, Merk, Teva, consulting fee from Genzyme, Merk and Novartis; SR received fee as speaking honoraria from Teva, Merck Serono, Biogen, travel grant from Biogen, Merck Serono, fee as advisory board consultant from Merck Serono and Novartis; NP received speaker fees from Biogen Idec and mission support from Novartis; CG received founding for travel and speaker honoraria from Bracco; CP received consulting and lecture fees and research funding and travel grants from Almirall, Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche and Teva; PP received founding for travel from Novartis, Genzyme and Bracco and speaker honoraria from Biogen.
: The study protocol reported in this manuscript has been approved by the the ethical committee of Policlinico Umberto I, Sapienza, University of Rome, Italy, and has been performed in accordance with those ethical standards listed in the Declaration of Helsinki.
: All subjects gave their informed consent prior inclusion in the study and details that might disclose their identity were omitted.